海曲泊帕在血小板减少症中的临床研究进展  

Clinical Research Progress of Hetrombopag in Thrombocytopenia

作　　者：张子颖 吴灵芝[1] 印妮[1] 王振欣[1] ZHANG Ziying;WU Lingzhi;YIN Ni;WANG Zhenxin(Department of Oncology,The First Affiliated Hospital of Soochow University,Suzhou 215000,China)

机构地区：[1]苏州大学附属第一医院肿瘤科,江苏苏州215000

出　　处：《中国药学杂志》2024年第15期1361-1365,共5页Chinese Pharmaceutical Journal

基　　金：江苏省社会发展面上项目资助(BE2022728)。

摘　　要：血小板减少症是一种以外周血中血小板计数减少为特征的疾病,可由多种先天性和后天疾病引起。目前治疗血小板减少症的促血小板生成药物主要包括重组人白细胞介素11(rhIL-11)、重组人血小板生成素(rhTPO)以及血小板生成素受体激动剂(TPO-RA)。海曲泊帕(hetrombopag)是一种新型的口服非肽类TPO-RA,已在中国获批用于治疗既往对糖皮质激素和免疫球蛋白等治疗反应不佳的慢性成人原发免疫性血小板减少症(ITP)和免疫抑制治疗疗效不佳的重型再生障碍性贫血(SAA)。临床研究数据表明,海曲泊帕用于ITP及SAA治疗的安全性及耐受性良好。目前海曲泊帕治疗化疗所致血小板减少症(CIT)的一项Ⅲ期临床研究正在进行中。本文就海曲泊帕在血小板减少症中的最新研究进展作一综述,以期为临床制定应对血小板减少症的有效策略或个性化防治方案提供参考。Thrombocytopenia is a disorder characterized by a decreased platelet count in the peripheral blood,which can be caused by various congenital and acquired diseases.Currently,thrombopoiesis-promoting drugs used for thrombocytopenia primarily include recombinant human interleukin-11(rhIL-11),recombinant human thrombopoietin(rhTPO),and thrombopoietin receptor agonist(TPORA).Hetrombopag is an innovative oral non-peptide TPO-RA that has been approved for treating chronic adult primary immune thrombocytopenia(ITP) with inadequate response to glucocorticoids and immunoglobulin,as well as severe aplastic anemia(SAA) with poor response to immunosuppressive therapy in China.Clinical studies have demonstrated that hetrombopag is safe and well-tolerated in ITP and SAA patients.Currently,there is an ongoing phase Ⅲ clinical trial investigating the efficacy of hetrombopag in managing chemotherapy-induced thrombocytopenia(CIT),This article provides a review on the research progress of hetrombopag in treating thrombocytopenia,aiming to offer valuable insights for clinical practice.

关 键 词：海曲泊帕 血小板生成素受体激动剂 免疫性血小板减少症 再生障碍性贫血 化疗所致血小板减少症 

分 类 号：R95[医药卫生—药学] R969